Programme
Preliminary Programme
Montevideo, Uruguay · 23–26 February 2027 · Arrival Monday 22.
Monday
22 FebArrival & registration
Tuesday
23 FebLaura Sepp-Lorenzino
Welcome from OTS and introduction to oligonucleotide therapeutics
Emanuele Buratti
Introduction to RNA splicing
Coffee break
Alberto Kornblihtt
Control of alternative splicing using siRNAs
Lunch
Pablo D. Dans
In-silico modelling of oligonucleotides
Victoria Calzada
Therapeutic aptamers
Coffee break
Invited lecture
Round table: The journey from the academic lab into global biotech
Short talks selected from submitted abstracts
Wednesday
24 FebManuel de la Mata
miRNAs and their degradation mechanisms
Federico Ariel
Long non-coding RNAs and RNAi in field crops for sustainable agriculture
Coffee break
Rodrigo Galindo-Murillo
Molecular Modeling of Antisense Oligonucleotide Analogs
Lunch — Winery visit
Frank Slack
Towards microRNA therapeutics in cancer
Modesto Orozco
pH-driven dynamics and mechanisms of LNP-mediated siRNA delivery
Coffee break
Zoya Ignatova
Expanding the functional landscape of tRNAs beyond translation into therapeutics
Poster session
Asado — Barbecue
Thursday
25 FebJuan Pablo Tosar
Naked RNA uptake, sensing, and endosomal escape
Saumya Das
Less may be more: the evolving role of tRNA-derived small RNAs in biology and therapeutics
Coffee break
Macarena Hernández
Therapeutic Aptamers in Clinical Translation: The ApTOLL Story
Lunch
Samir El Andaloussi
Extrahepatic delivery of RNA and CRISPR therapeutics using engineered non-viral delivery systems
Annemieke Aartsma-Rus
Exon skipping for Duchenne muscular dystrophy: applying 25 years of expertise to future optimization
Coffee break
Adrián R. Krainer
The making of Nusinersen and current frontiers in splice-switching ASOs
Alberto Kornblihtt
ASOs, transcription and chromatin structure
Isabel Aznarez
Regulation of mRNA decay with ASOs for gene expression activation
Friday
26 FebInvited talk to be confirmed
Muthiah Manoharan
New frontiers and current challenges in siRNA design
Coffee break
Laura Sepp-Lorenzino
CRISPR Therapeutics: ex vivo and in vivo
Winery visit & farewell